CANNABINOID BASED COMPOSITION FOR MITIGATION OF VIRAL EFFECTS

CROSS-REFERENCE TO RELATED APPLICATIONS

[00001] The present patent application claims the priority benefit of U.S. provisional patent application 63/000,032 filed March 26, 2020, the disclosure of which is incorporated by reference herein.

BACKGROUND OF THE DISCLOSURE

1. Field of the Invention

[00002] The present disclosure relates to carmabinoid compositions and systems for administering of cannabinoid compositions. More specifically, the present disclosure relates to methods of using cannabinoid compositions for alleviating viral symptoms, reducing viral replication, suppressing inflammation, and/or improving an immune response to viral infections.

2. Description of the Related Art

[00003] Cannabis is a genus of flowering plants that have three different spedes: Cannabis sativa, Cannabis Indica, and Cannabis ruderalis. Cannabis has long been used for hemp fiber, seed, seed oils, medicinal purposes, and as a recreational drug. There are at least 110 different phyto-cannabinoids contained in the cannabis plant. The most well-known major cannabinoid is tetrahydrocannabinol (THC), the psychoactive compound that has euphoric affects. THC has a unique molecular composition relative to other cannabinoids, as well as unique therapeutic and medicinal properties. THC is a bronchodilator, muscle relaxant, anti-spasmodic, powerful neuroprotectant, and antioxidant. Recent clinical evidence has shown THC to have anti-tumoral properties as well.

[00004] The other major cannabinoid is cannabidiol (CBD), which also has a unique molecular composition as well as unique therapeutic and medicinal effects. CBD is best known for its relationship to the hemp plant, a form of cannabis with low THC that historically has been used primarily for industrial purposes. [00005] Cannabis contains at least 483 known chemical compounds, which include cannabinoids, terpenoids, flavonoids, nitrogenous compounds, amino adds, proteins, glycoproteins, enzymes, sugars and related compounds, hydrocarbons, simple alcohols, aldehydes, ketones, simple adds, fatty adds, simple esters, ladones, steroids, terpenes, non- cannabinoid phenols, vitamins, pigments, and elements. These compounds are secreted on the glandular trichomes.

[00006] The structure of all viruses includes a protein shell called a capsid which encloses its genetic material. Viral genomes may vary in the type of genetic material (DNA or RNA), and its organization (single- or double-stranded, linear or circular, and segmented or non- segmented). Segmented virus genomes are those that are divided into two or more physically separate molecules of nucleic add, all of which are then packaged into a single virus particle. Non-segmented virus genomes may consist of a single segment of genetic material.

[00007] Enveloped viruses have an additional layer that covers the capsid ( e.g ., composed of lipids, proteins, and glycoproteins), which is not present in non-enveloped viruses. Enveloped viruses enter the host cell by membrane fusion, either from an internal compartment following an endocytic step or at the cell surface. Glycoproteins embedded in the envelope are used to attach to host cells. Non-enveloped viruses only need their protein- based capsid and host detedor proteins to infect host cells. Because of the fragility of the envelope, non-enveloped viruses are more resistant to changes in pH and temperature, as well as more resistant to some common disinfectants. The lipid envelope on enveloped viruses can be disrupted by conventional disinfectants or soaps, destroying their ability to infect host cells.

[00008] Well-known enveloped viruses include herpes virus, influenza virus, paramyxovirus, respiratory syncytial virus, coronavirus, HIV, hepatitis B virus, hepatitis C virus, SARS-CoV, etc. Non-enveloped viruses (often referred to as "naked" viruses) may include Picornaviridae, Reoviridae, Caldviridae, Adenoviridae, and Parvo Viridae (Parvoviridae). Members of these families include rhinovirus, poliovirus, adenovirus, hepatitis A virus, norovirus, papillomavirus, and rotavirus. An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (S ARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. [00009] Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronaviruses are enveloped, non-segmented, positive strain RNA viruses. In late 2019, the disease began to spread from its origin in the Hubei province of China, and by early 2020, there were reported cases in essentially all developed nations leading to its classification as a pandemic. By early 2021, the WHO was reporting over 95 million confirmed cases and over 2.1 million deaths. [00010] COVID-19 presents a unique challenge to providing medical care. While symptoms to many young, healthy individuals may be mild (e.g., runny nose, sore throat, cough, fever, and difficulty breathing in severe cases), the disease can be fatal to the elderly and/or those with comorbidities. The virus is also highly infectious, allowing a single individual to infect thousands of others in a short period of time through the course of normal sodal interactions.

[00011] Most people infected with the COVID-19 virus may experience mild to moderate respiratory illness and recover without requiring special treatment. While many otherwise healthy people successfully recover from COVID-19 without medical intervention, older people and those with underlying medical problems (e.g., cardiovascular disease, diabetes, chronic respiratory disease, and cancer) are more likely to develop serious illness. Such individuals may need specific medical treatments and tools, such as respiratory ventilators, continuous positive air pressure (CPAP) devices, oxygen tanks, etc., which can be scarce in times of crisis. Scarcity of these life-saving devices can increase the rate of mortality in specific locations if the local medical system becomes overwhelmed. In 2020, infection rates and comorbidity in Italy quickly overwhelmed the medical system and caused higher rates of death associated with COVID-19 than may otherwise have been necessary.

[00012] Even with the development and distribution of effective vaccines for COVID-19, a natural antiviral solution with minimal side effects that can be used alone or in conjunction with vacdnes as a preventative treatment is desirable. Some individuals may not be vaccinated due to personal choice or health limitations. Further, mitigation of the spread of the disease has presented significant challenges for world governments, local medical facilities, and individuals. Quarantines and self-isolation may slow spread, but are difficult and problematic to enforce, as well as causing significant negative economic impact that endangers vulnerable members of society. [00013] Moreover, variants of SARS-CoV-2 are emerging which may prove to be vaccine- resistant and may lead to further surges in infections. In addition, there is growing evidence that for some individuals, there may be long-term health complications from COVID-19 with many patients experiencing persistent respiratory and other symptoms months after their initial illness. Such problems may include chronic cough, fibrotic lung disease, bronchiectasis and pulmonary vascular disease. Coronavirus tends to target alveolar epithelial cells, and there is evidence implicating other viruses infecting these cells ( e.g ., herpes viruses).

Infection with SARS-CoV-2 may reduce the cell's ability to respond effectively to viral encounter by other viruses. There exists a need for therapeutic formulations to mitigate the symptoms and spread of respiratory infections like COVID-19.

[00014] When COVID-19 symptoms present themselves, the body may fight the virus so that over time, the body can develop its own immunity. Anything that would help mitigate some of the symptoms, to lessen the impact on the body and the individuals well-being, may be helpful to recover from the COVID-19 virus affects. There is a need for mitigating symptoms for COVID-19.

[00015] When an individual fights a virus off, such as COVID-19, it would be helpful to use safe, low cost means to mitigate the symptoms. It is well-known that the drug companies and governments are spending large amounts of money for a cure or a vaccination, but what is also needed is a low-cost, easy to use, safe means to lower the COVID-19 virus effects.

[00016] There is a need for a safe and effective treatment for preventing, mitigating the symptoms, and reducing the infectiousness of viral diseases and pathogens such as COVID- 19.

BRIEF DESCRIPTIONS OF THE DRAWINGS

[00017] FIG. 1 illustrates a diagram of an exemplary carmabinoid composition, a diagram of an exemplary method for preparing carmabinoid compositions, and a diagram of exemplary forms of carmabinoid compositions.

[00018] FIG. 2 is a detailed table of components of an exemplary carmabinoid composition.

[00019] FIG. 3 is a flowchart illustrating exemplary steps of a method of preparing a cannabinoid composition for a user and associated modules.

[00020] FIG. 4 is a table of exemplary forms in which the cannabinoid composition may be provided.

SUMMARY OF THE CLAIMED INVENTION

[00021] Embodiments of the present invention include compositions and methods for formulating compositions that mitigate the effects of catching or having a virus. In certain embodiments, the carmabinoid compositions may provide a synergistic effect of mitigating the symptoms of a viral infection. In some cases, the synergistic effect is achieved by formulating certain cannabinoid compositions in specific forms for administration, such as in the form of a lozenge, a nasal spray, a nasal gel, an oral spray, etc. The disclosure provides effective and economical compositions and methods for the treatment of viral infections. [00022] Embodiments of the disclosure relate to cannabinoid compositions and systems for administering of such cannabinoid compositions. Additional embodiments of the disclosure relate to methods for alleviating viral symptoms, reducing viral replication, suppressing inflammation, and/or improving an immune response to viral infections.

[00023] In some embodiments of the present disclosure, the cannabinoid composition provides therapeutic effects for victims of infectious diseases caused by viral infections, such as Coronavirus Disease 2019 (COVID-19). The cannabinoid compositions may, in some cases, be self-administered by patients as a means of preventing infection by viruses, mitigating the symptoms of viral infections, and lowering infectiousness of patients. Embodiments of the present disclosure would overall contribute to slowing or limiting disease impacts and minimizing general socioeconomic disruption, both short- and long term.

[00024] FIG. 1 illustrates a diagram of an exemplary cannabinoid composition for viral treatment, a diagram of an exemplary method for preparing cannabinoid compositions, and a diagram of exemplary forms of cannabinoid compositions. FIG. 2 is a detailed table of components of an exemplary cannabinoid composition.

[00025] As illustrated in the table of FIG. 2, the cannabinoid compositions may include:

(a) about 0.1 wt.% to about 10 wt.% of one or more cannabinoids, and

(b) about 1 wt.% to about 55 wt.% of a zinc compound, wherein all weight percentages are based on the total weight of the composition.

[00026] In some embodiments, a cannabinoid composition is provided including at least one cannabinoid, at least one zinc compound, and at least one terpene. [00027] According to some embodiments, a cannabinoid composition is provided that includes at least one cannabinoid, at least one zinc compound, and at least one zinc ionophore.

[00028] According to some embodiments, a cannabinoid composition may be provided that includes at least one cannabinoid, at least one zinc compound, at least one terpene, and at least one zinc ionophore.

[00029] According to some embodiments, the cannabinoid compositions provided may be used in the treatment of infectious diseases caused by viral infections. As used herein, the term "treatment" or "treat" includes preventing, curing, ameliorating, mitigating, and reducing the instances or severity of a condition or a symptom thereof.

[00030] According to some embodiments, the compositions provided may be used in the treatment of diseases caused by bacterial infections, fungal infections, or environmental allergens.

[00031] Some embodiments provide a method that includes administering an effective amount of the cannabinoid composition described herein to a subject in need thereof, such as one suffering from a respiratory disease or ailment. Methods of treating such ailments are provided. As used herein, the term "administering" includes any mode of administration, such as oral, subcutaneous, sublingual, transmucosal, parenteral, intravenous, intra-arterial, buccal, sublingual, topical, vaginal, rectal, ophthalmic, nasal, inhaled, intramuscular, intraosseous, intrathecal, and transdermal, or combinations thereof. Different cannabinoid composition forms may include, but not limited to lozenge, chewable tablet, chewable gummy, effervescent powder, tablet, capsule, syrup, mouth rinse, powder, flavored powder, oil drops, oral dissolvable strip, oral spray, nasal spray, aerosol inhalable liquid, inhalable powder, transdermal cream, gel, patch, or suppository.

DETAILED DESCRIPTION

[00032] Embodiments of the disclosure relate to cannabinoid compositions and systems for administering of such cannabinoid compositions. Additional embodiments of the disclosure relate to methods for alleviating viral symptoms, reducing viral replication, suppressing inflammation, and/or improving an immune response to viral infections. Such compositions and methods may be based on cannabinoids and their associated wide-ranging health effects that are based on different specific cannabinoids and the binding to CBi receptor and CB2 receptors. CBi receptors are located in the central and peripheral nervous system and inhabits an orthostatic and several allosteric binding sites for potential ligand bindings. Due to its distribution through the nervous system, activation of CBi receptors influences various cognitive processes ( e.g ., attention, memory, motoric functions and pain reception). Inhibition of CBi receptors through CBi antagonists provides an expanding pharmaceutical applicability to target such conditions as obesity, opioid abuse, and/or Parkinson disease.

[00033] The CB2 receptor is predominantly located in the peripheral tissues of the immune system and the gastrointestinal system, but can also be found in neurons of the brain. CB2 receptors therefore can promote anti-inflammatory and immune modulatory (e.g., immune suppression, induction of apoptosis, and induction of cell migration), therapeutic effects. Additionally, CB2 receptors have a potential therapeutic role in the treatment of neurodegenerative disorders such as Alzheimer's disease.

[00034] Notwithstanding the various bases for having such effects, it was unexpected that certain cannabinoids (e.g., cannabidiol and cannabigerols) may operate to alleviate one or more viral symptoms, reduce viral replication, advantageously influence viral pathogenesis, and/or generally improve the immune system of a user. Further, various anti-inflammatory and immuno-modulatory activity of the cannabinoid compositions may be able to suppress inflammation and modulate the development of immune responses to viral infections. [00035] Additional embodiments of the present disclosure further include use of certain cannabinoid compositions disclosed herein to downregulate the expression of pro- inflammatory cytokines and pathways involved in inflammation and fibrosis. For instance, the cannabinoid compositions may exhibit anti-inflammatory activity in COVID-19 related inflammation in lung epithelial cells. COVID-19 disease pathogenesis may include hyper induction of proinflammatory cytokines, also known as cytokine storm, which may precede acute respiratory distress syndrome (ARDS). Cytokines may also partake in the molecular pathogenesis of lung fibrosis. As such, cannabinoid compositions— and methods and systems of preparation and administration thereof —may provide significant advantages with alleviating symptoms and, in some cases, reducing the harm associated with viral infections such as COVID-19.

[00036] The cannabinoid compositions may include:

(a) about 0.1 wt.% to about 10 wt.% of one or more cannabinoids, and

(b) about 1 wt.% to about 55 wt.% of a zinc compound, wherein all weight percentages are based on the total weight of the composition.

[00037] The activity of the formulation may be enhanced when at least one cannabinoid is combined with at least one zinc compound due to synergistic or additive effects between the individual components. In various embodiments, the cannabinoid compositions have a weight ratio of the total amount of cannabinoids to the total amount of zinc compounds of about 1:100 to about 1:1. For example, the weight ratio of the total amount of cannabinoids to the total amount of zinc compounds may be about 1:100 to about 1:1, about 1:90 to about 1:1, about 1:80 to about 1:1, about 1:70 to about 1:1, about 1:60 to about 1:1, about 1:50 to about 1:1, about 1:40 to about 1:1, about 1:30 to about 1:1, about 1:20 to about 1:1, about 1:10 to about 1:1, about 1:100 to about 1:10, about 1:90 to about 1:10, about 1:80 to about 1:10, about 1:70 to about 1:10, about 1:60 to about 1:10, about 1:50 to about 1:10, about 1:40 to about 1:10, about 1:30 to about 1:10, about 1:20 to about 1:10, about 1:100 to about 1:20, about 1:90 to about 1:20, about 1:80 to about 1:20, about 1:70 to about 1:20, about 1:60 to about 1:20, about 1:50 to about 1:20, about 1:40 to about 1:20, about 1:30 to about 1:20, about 1:100 to about 1:30, about 1:90 to about 1:30, about 1:80 to about 1:30, about 1:70 to about 1:30, about 1:60 to about 1:30, about 1:50 to about 1:30, about 1:40 to about 1:30, about 1:100 to about 1:40, about 1:90 to about 1:40, about 1:80 to about 1:40, about 1:70 to about 1:40, about 1:60 to about 1:40, about 1:50 to about 1:40, about 1:100 to about 1:50, about 1:90 to about 1:50, about 1:80 to about 1:50, about 1:70 to about 1:50, or about 1:60 to about 1:50.

[00038] Suitable components/ingredients, such as those listed below, may be included or excluded from the formulations for cannabinoid compositions depending on the specific combination of other components/ingredients, the form of the carmabinoid composition (e.g., an emulsion, an oral spray, a nasal spray, a nasal gel, a lozenge, a tablet, a chewable tablet, a capsule, a gummy candy, an oral strip, a powder, etc.), and/or the use of the cannabinoid composition.

[00039] Cannabinoid (s')

[00040] The carmabinoid compositions may include one or more carmabinoid compounds in an amount from about 0.1 to about 10 wt.% based on the total weight of the cannabinoid composition. In some instances, the amount of carmabinoid compounds present in the cannabinoid composition may be from about 0.1 to about 10 wt.%, about 0.1 to about 9 wt.%, about 0.1 to about 8 wt.%, about 0.1 to about 7 wt.%, about 0.1 to about 6 wt.%, about 0.1 to about 5 wt.%, about 0.1 to about 4 wt.%, about 0.1 to about 3 wt.%, about 0.1 to about 2 wt.%, about 0.1 to about 1 wt.%, about 0.2 to about 10 wt.%, about 0.2 to about

9 wt.%, about 0.2 to about 8 wt.%, about 0.2 to about 7 wt.%, about 0.2 to about 6 wt.%, about 0.2 to about 5 wt.%, about 0.2 to about 4 wt.%, about 0.2 to about 3 wt.%, about 0.2 to about 2 wt.%, about 0.2 to about 1 wt.%, about 0.5 to about 10 wt.%, about 0.5 to about 9 wt.%, about 0.5 to about 8 wt.%, about 0.5 to about 7 wt.%, about 0.5 to about 6 wt.%, about 0.5 to about 5 wt.%, about 0.5 to about 4 wt.%, about 0.5 to about 3 wt.%, about 0.5 to about 2 wt.%, about 0.5 to about 1 wt.%, about 1 to about 10 wt.%, about 1 to about 9 wt.%, about 1 to about 8 wt.%, about 1 to about 7 wt.%, about 1 to about 6 wt.%, about 1 to about 5 wt.%, about 1 to about 4 wt.%, about 1 to about 3 wt.%, about 1 to about 2 wt.%, about 2 to about

10 wt.%, about 2 to about 9 wt.%, about 2 to about 8 wt.%, about 2 to about 7 wt.%, about 2 to about 6 wt.%, about 2 to about 5 wt.%, about 2 to about 4 wt.%, about 2 to about 3 wt.%, about 4 to about 10 wt.%, about 4 to about 9 wt.%, about 4 to about 8 wt.%, about 4 to about 7 wt.%, about 4 to about 6 wt.%, or about 4 to about 5 wt.%, including ranges and subranges therebetween, based on the total weight of the carmabinoid composition.

[00041] The cannabinoid(s) may be chosen from CBD (cannabidiol), CBDA (cannabidiolic add), CBN (cannabinol), CBG (cannabigerol), CBC (cannabichromene), CBL (cannabicyclol), CBV (cannabivarin), THCV (tetrahydrocannabivarin), CBDV (cannabidivarin), CBCV (cannabichromevarin), CBGV (cannabigerovarin), CBGM (cannabigerol monomethyl ether), CBE (cannabielsoin), or CBT (cannabicitran). In some instances, the carmabinoid composition includes two or more, three or more, four or more, or five or more cannabinoid compounds chosen from CBD, CBDA, CBN, CBG, CBC, CBL, CBV, THCV, CBDV, CBCV, CBGV, CBGM, CBE, and CBT. The cannabinoid(s) (e.g., CBD and CBG compounds) may be extracted from Cannabis sativa, Cannabis indica, Cannabis ruderalis, or their mixture. In addition to benefits and advantages discussed herein, the cannabinoid compositions may provide the following compounds and effects.

[00042] Cannabigerol (CBG) is a minor constituent of cannabis. During growth, most of the cannabigerol may be converted into other cannabinoids, primarily tetrahydrocannabinol (THC) or cannabidiol (CBD), e.g., leaving about 1% CBG in the plant.

[00043] Cannabigerolic add (CBGa) may be useful to provide anti-proliferative and to encourage apoptosis, as well as have anti-inflammatory and analgesic properties.

[00044] Another psychoactive cannabinoid, tetrahydrocanabivarinic (THCv), may be useful to provide appetite suppressant and an effective stimulator of bone growth, as well as reducing intensity of panic attacks, and Alzheimer' s-related conditions.

[00045] Cannabinol (CBN) may be useful to help with insomnia, pain relief, the promotion of bone growth, provide anti-convulsive properties, and to be effective as an appetite stimulant.

[00046] Cannabichromene (CBC) may be useful to provide relieve pain, anti-epileptic properties, reduce inflammation, promote bone growth, and have has anti- proliferative properties.

[00047] Cannabidiolic acid (CBDa) may be useful to provide anti-inflammatory properties, anti-bacterial properties, anti-nausea properties, and anti-proliferative properties. [00048] Tetrahydrocannabinolic add (THCa) may be useful to provide anti-inflammatory properties, anti-nausea properties, neuroprotective properties, and anti-proliferative properties.

[00049] A8-THC, A8-tetrahydrocannabinol, which is a psychoactive cannabinoid like THC, may be a useful anti-emetic and useful to boost acetylcholine, deficiencies of which are thought to contribute to cognitive disorders, such as Alzheimer's.

[00050] Zinc Compound

[00051] The cannabinoid compositions may include one or more zinc compounds in an amount from about 0.5 to about 55 wt.% based on the total weight of the cannabinoid composition. In some instances, the amount of zinc compounds present in the cannabinoid composition may be from about 0.5 to about 55 wt.%, about 0.5 to about 50 wt.%, about 0.5 to about 45 wt.%, about 0.5 to about 40 wt.%, about 0.5 to about 35 wt.%, about 0.5 to about 30 wt.%, about 0.5 to about 25 wt.%, about 0.5 to about 20 wt.%, about 0.5 to about 0.55 wt.%, about 0.5 to about 0.50 wt.%, about 0.5 to about 5 wt.%, about 1 to about 55 wt.%, about 1 to about 50 wt.%, about 1 to about 45 wt.%, about 1 to about 40 wt.%, about 1 to about 35 wt.%, about 1 to about 30 wt.%, about 1 to about 25 wt.%, about 1 to about 20 wt.%, about 1 to about 15 wt.%, about 1 to about 10 wt.%, about 1 to about 5 wt.%, about 5 to about 55 wt.%, about 5 to about 50 wt.%, about 5 to about 45 wt.%, about 5 to about 40 wt.%, about 5 to about 35 wt.%, about 5 to about 30 wt.%, about 5 to about 25 wt.%, about 5 to about 20 wt.%, about 5 to about 55 wt.%, about 5 to about 10 wt.%, about 10 to about 55 wt.%, about 10 to about 50 wt.%, about 10 to about 45 wt.%, about 10 to about 40 wt.%, about 10 to about 35 wt.%, about 10 to about 30 wt.%, about 10 to about 25 wt.%, about 10 to about 20 wt.%, about 10 to about 15 wt.%, about 15 to about 55 wt.%, about 15 to about 50 wt.%, about 15 to about 45 wt.%, about 15 to about 40 wt.%, about 15 to about 35 wt.%, about 15 to about 30 wt.%, about 15 to about 25 wt.%, about 15 to about 20 wt.%, about 20 to about 55 wt.%, about 20 to about 50 wt.%, about 20 to about 45 wt.%, about 20 to about 40 wt.%, about 20 to about 35 wt.%, about 20 to about 30 wt.%, about 20 to about 25 wt.%, about 25 to about 55 wt.%, about 25 to about 50 wt.%, about 25 to about 45 wt.%, about 25 to about 40 wt.%, about 25 to about 35 wt.%, about 25 to about 30 wt.%, about 30 to about 55 wt.%, about 30 to about 50 wt.%, about 30 to about 45 wt.%, about 30 to about 40 wt.%, about 30 to about 35 wt.%, about 35 to about 55 wt.%, about 35 to about 50 wt.%, about 35 to about 45 wt.%, about 35 to about 40 wt.%, about 40 to about 55 wt.%, about 40 to about 50 wt.%, about 40 to about 45 wt.%, about 45 to about 55 wt.%, or about 45 to about 50 wt.%, including ranges and subranges therebetween, based on the total weight of the carmabinoid composition.

[00052] Zinc is found and operates in every cell of the human body. Zinc is a non-lipid soluble mineral and so requires transport systems to cross cell membranes, including zinc binding proteins. Zinc-binding proteins are located in cell membranes and can facilitate transport of zinc into cells.

[00053] Zinc, particularly in combination with certain cannabinoids, may have a beneficial effect in reducing the replication of viruses such as COVID-19, thereby alleviating symptoms of a viral infection, and/or for treating a viral infection. Additionally, such beneficial effect ( e.g ., synergistic effect) may be enhanced by administering the cannabinoid compositions in the form of a lozenge.

[00054] The cannabinoid compositions may be formulated to deliver a dosage amount of about 12 to about 150 mg of zinc ion (also referred to a free zinc) and/or up to about 220 mg of a zinc compound (e.g., zinc sulfate). High-dose, long-term zinc supplementation may decrease the plasma concentrations of certain quinolone (e.g., ciprofloxacin) and tetracycline antibiotics, as with other divalent metals (e.g., calcium).

[00055] The zinc compound(s) contain at least one zinc atom. Examples of zinc compounds that may be present in the cannabinoid composition include zinc, zinc ions such as divalent zinc ions, zinc salts such as divalent zinc salts, zinc hydrates such as zinc salt hydrates (e.g., zinc sulfate heptahydrate), and zinc oxides. Non-limiting examples of zinc salts include inorganic zinc salts and organic zinc salts. The zinc compounds may be chosen from organic zinc salts, such as zinc carboxylate, zinc hydroxycarboxylate, zinc aminocarboxylate, and a mixture thereof. Additionally or alternatively, the zinc compounds may be chosen from zinc, zinc chloride, zinc acetate, zinc citrate, sudoxicam zinc, zinc sulfate, zinc nitrate, zinc carbonate, zinc tartrate, zinc malate, zinc lactate, zinc aminoacetate, zinc aspartate, zinc propionate, zinc oleate, zinc stearate, zinc valerate, zinc benzoate, zinc gluconate, zinc butyrate, zinc formate, zinc glycerate, zinc glycolate, zinc oxide, zinc maleate, zinc malonate, zinc succinate, zinc ethylenediaminetetraacetate, zinc pentosan polysulfate, zinc oxyacetate, hydrates thereof, and mixtures thereof. In some embodiments the zinc compound is selected from the group consisting of zinc, zinc chloride, zinc acetate, zinc citrate, sudoxicam zinc, zinc sulfate, zinc nitrate, zinc carbonate, zinc tartrate, zinc malate, zinc lactate, zinc aminoacetate, zinc aspartate, zinc propionate, zinc oleate, zinc benzoate, zinc gluconate, zinc butyrate, zinc formate, zinc glycerate, zinc glycolate, zinc oxide, zinc pentosan polysulfate, zinc oxyacetate, hydrates thereof, and mixtures thereof.

The zinc compounds may be in an encapsulated form.

[00056] In some cases, the cannabinoid composition may include zinc ionophore(s).

Zinc ionophores are lipid-soluble substances that can transport non-lipid soluble elements across the cell membrane. Zinc ionophores are zinc transporters in and out of the cell and can increase the effects of zinc in the cell. In some cases, the cannabinoid composition may include zinc ionophore in an amount of about 0.1 to about 10 wt.%, about 0.1 to about 9 wt.%, about 0.1 to about 8 wt.%, about 0.1 to about 7 wt.%, about 0.1 to about 6 wt.%, about 0.1 to about 5 wt.%, about 0.1 to about 4 wt.%, about 0.1 to about 3 wt.%, about 0.1 to about 2 wt.%, about 0.1 to about 1 wt.%, about 0.2 to about 10 wt.%, about 0.2 to about 9 wt.%, about 0.2 to about 8 wt.%, about 0.2 to about 7 wt.%, about 0.2 to about 6 wt.%, about 0.2 to about 5 wt.%, about 0.2 to about 4 wt.%, about 0.2 to about 3 wt.%, about 0.2 to about 2 wt.%, about 0.2 to about 1 wt.%, about 0.5 to about 10 wt.%, about 0.5 to about 9 wt.%, about 0.5 to about 8 wt.%, about 0.5 to about 7 wt.%, about 0.5 to about 6 wt.%, about 0.5 to about 5 wt.%, about 0.5 to about 4 wt.%, about 0.5 to about 3 wt.%, about 0.5 to about 2 wt.%, about 0.5 to about 1 wt.%, about 1 to about 10 wt.%, about 1 to about 9 wt.%, about 1 to about 8 wt.%, about 1 to about 7 wt.%, about 1 to about 6 wt.%, about 1 to about 5 wt.%, about 1 to about 4 wt.%, about 1 to about 3 wt.%, about 1 to about 2 wt.%, about 2 to about 10 wt.%, about 2 to about 9 wt.%, about 2 to about 8 wt.%, about 2 to about 7 wt.%, about 2 to about 6 wt.%, about 2 to about 5 wt.%, about 2 to about 4 wt.%, about 2 to about 3 wt.%, about 4 to about 10 wt.%, about 4 to about 9 wt.%, about 4 to about 8 wt.%, about 4 to about 7 wt.%, about 4 to about 6 wt.%, or about 4 to about 5 wt.%, including ranges and subranges therebetween of zinc ionophore, based on the total weight of the cannabinoid composition.

[00057] The cannabinoid compositions may have a weight ratio of the total amount of zinc ionophore(s) to total amount of zinc compound(s) of about 3:1 to about 1:10. For example, the weight ratio of the total amount of zinc ionophore to the total amount of zinc compound may be about 3:1 to about 1:10, about 2:1 to about 1:10, about 1:1 to about 1:10, about 3:1 to about 1:9, about 3:1 to about 1:8, about 3:1 to about 1:7, about 3:1 to about 1:6, about 3:1 to about 1:5, about 3:1 to about 1:4, about 3:1 to about 1:3, about 3:1 to about 1:2, about 3:1 to about 1:1, or any range or subrange thereof. In some embodiments, the weight ratio of zinc ionophore to zinc compound is about 1:3.

[00058] Additionally or alternatively, the cannabinoid compositions may have a weight ratio of the total amount of zinc ionophore(s) to zinc ions (also referred to a free zinc) of about 3:1 to about 1:10. For instance, the weight ratio of the total amount of zinc ionophores to the total amount of zinc ions may be about 3:1 to about 1:10, about 2:1 to about 1:10, about 1:1 to about 1:10, about 3:1 to about 1:9, about 3:1 to about 1:8, about 3:1 to about 1:7, about 3:1 to about 1:6, about 3:1 to about 1:5, about 3:1 to about 1:4, about 3:1 to about 1:3, about 3:1 to about 1:2, about 3:1 to about 1:1, or any range or subrange thereof. In some embodiments, the weight ratio of zinc ionophore to zinc ions is about 1:3.

[00059] Magnesium Compound tsi

[00060] The cannabinoid compositions may, in some cases, include one or more magnesium compounds. The amount of the magnesium compound(s) present in the cannabinoid compositions may be about 1 to 40 wt.% based on the total weight of the cannabinoid composition. In some instances, the total amount of the magnesium compound(s) present in the cannabinoid composition may be about 1 to about 40 wt.%, about 1 to about 35 wt.%, about 1 to about 30 wt.%, about 1 to about 25 wt.%, about 1 to about 20 wt.%, about 1 to about 15 wt.%, about 1 to about 10 wt.%, about 1 to about 5 wt.%, about 3 to about 40 wt.%, about 3 to about 35 wt.%, about 3 to about 30 wt.%, about 3 to about 25 wt.%, about 3 to about 20 wt.%, about 3 to about 55 wt.%, about 3 to about 10 wt.%, about 5 to about 40 wt.%, about 5 to about 35 wt.%, about 5 to about 30 wt.%, about 5 to about 25 wt.%, about 5 to about 20 wt.%, about 5 to about 55 wt.%, about 5 to about 10 wt.%, about 10 to about 40 wt.%, about 10 to about 35 wt.%, about 10 to about 30 wt.%, about 10 to about 25 wt.%, about 10 to about 20 wt.%, about 10 to about 15 wt.%, about 15 to about 40 wt.%, about 15 to about 35 wt.%, about 15 to about 30 wt.%, about 15 to about 25 wt.%, about 15 to about 20 wt.%, about 20 to about 40 wt.%, about 20 to about 35 wt.%, about 20 to about 30 wt.%, about 20 to about 25 wt.%, about 25 to about 40 wt.%, about 25 to about 35 wt.%, about 25 to about 30 wt.%, about 30 to about 40 wt.%, or about 30 to about 35 wt.%, including ranges and subranges therebetween, based on the total weight of the cannabinoid composition.

[00061] The magnesium compound(s) may provide a source of magnesium ion (also referred to as free magnesium or Mg ²⁺ ) that is rapidly absorbed through the lining of the user's stomach. In various embodiments, the soluble magnesium compound is provided in a manner that reduces gastrointestinal distress commonly associated with the consumption of the magnesium. For example, the cannabinoid composition may be formulated such that the magnesium compounds have a high absorption rate of across the stomach lining, thus preventing large amount of magnesium from entering into the small intestine. The magnesium compounds may be chosen from magnesium oxide, magnesium chloride, magnesium citrate, magnesium gluconate, magnesium glycinate, magnesium threonate, and magnesium stearate, and a mixture thereof. In some cases, the magnesium salt is derived ( e.g ., from one of the foregoing magnesium compounds) utilizing an amino add constituent. In some embodiments, the magnesium compound is magnesium citrate, magnesium stearate, magnesium glydnate, or a mixture thereof.

[00062] Terpene/sl

[00063] The cannabinoid compositions may include one or more terpenes in an amount from about 0.1 to about 10 wt.% based on the total weight of the cannabinoid composition.

In some instances, the amount of terpenes present in the cannabinoid composition may be from about 0.1 to about 10 wt.%, about 0.1 to about 9 wt.%, about 0.1 to about 8 wt.%, about 0.1 to about 7 wt.%, about 0.1 to about 6 wt.%, about 0.1 to about 5 wt.%, about 0.1 to about 4 wt.%, about 0.1 to about 3 wt.%, about 0.1 to about 2 wt.%, about 0.1 to about 1 wt.%, about 0.2 to about 10 wt.%, about 0.2 to about 9 wt.%, about 0.2 to about 8 wt.%, about 0.2 to about 7 wt.%, about 0.2 to about 6 wt.%, about 0.2 to about 5 wt.%, about 0.2 to about 4 wt.%, about 0.2 to about 3 wt.%, about 0.2 to about 2 wt.%, about 0.2 to about 1 wt.%, about 0.5 to about 10 wt.%, about 0.5 to about 9 wt.%, about 0.5 to about 8 wt.%, about 0.5 to about 7 wt.%, about 0.5 to about 6 wt.%, about 0.5 to about 5 wt.%, about 0.5 to about 4 wt.%, about 0.5 to about 3 wt.%, about 0.5 to about 2 wt.%, about 0.5 to about 1 wt.%, about 1 to about 10 wt.%, about 1 to about 9 wt.%, about 1 to about 8 wt.%, about 1 to about 7 wt.%, about 1 to about 6 wt.%, about 1 to about 5 wt.%, about 1 to about 4 wt.%, about 1 to about 3 wt.%, about 1 to about 2 wt.%, about 2 to about 10 wt.%, about 2 to about 9 wt.%, about 2 to about 8 wt.%, about 2 to about 7 wt.%, about 2 to about 6 wt.%, about 2 to about 5 wt.%, about 2 to about 4 wt.%, about 2 to about 3 wt.%, about 4 to about 10 wt.%, about 4 to about 9 wt.%, about 4 to about 8 wt.%, about 4 to about 7 wt.%, about 4 to about 6 wt.%, or about 4 to about 5 wt.%, including ranges and subranges therebetween, based on the total weight of the cannabinoid composition.

[00064] In various embodiments, the terpenes are derived and/or found in the cannabis plant. As used herein, cannabis terpenes refer to terpenes and/or terpenoids that are found in the cannabis plant, regardless of whether the terpene and/or terpenoids is extracted from a cannabis plant or synthesized/manufactured by human activity. Terpenes are a group of plant hydrocarbons formed by the polymerization of 5-carbon isoprene (QHe) subunits. Terpenes are one of the largest and most varied group of plant chemicals. The terpenes may be chosen from monoterpenes, sesquiterpenes, and a mixture thereof. In some cases, the terpenes are volatile at room temperature. The terpenes may be an essential oil.

[00065] The terpenes may be chosen from pinene, limonene, caryophyllene, caryophyllene oxide, nerolidol, eucalyptol, terpinene, terpineol, myrcene, cycloartenol, dtronellol, amyrin, camphene, cymene, odmene, humulene, famesene, guaiol, eudesmol, friedelin, linalool, camphor, menthol, thymol, carvacrol, eugenol, farnesol, dtronellol, geraniol, citral, and a mixture thereof. In at least one instance, the terpene is chosen from alpha-pinene, beta-myrcene, beta-pinene, ocimene peak 1, limonene, ocimene peak 2, alpha- cedrene, trans-caryophyllene, alpha-humulene, valencene, cis-nerolidol, trans-nerolidol, trans-nerolidol, guaiol, caryophyllene oxide, cedrol, alpha-bisabolol, and a mixture thereof. [00066] Flavonoid/s')

[00067] The cannabinoid compositions may include one or more flavonoid(s) in an amount from about 0.1 to about 10 wt.% based on the total weight of the cannabinoid composition. In some instances, the amount of flavonoid(s) present in the cannabinoid composition may be from about 0.1 to about 10 wt.%, about 0.1 to about 9 wt.%, about 0.1 to about 8 wt.%, about 0.1 to about 7 wt.%, about 0.1 to about 6 wt.%, about 0.1 to about 5 wt.%, about 0.1 to about 4 wt.%, about 0.1 to about 3 wt.%, about 0.1 to about 2 wt.%, about 0.1 to about 1 wt.%, about 0.2 to about 10 wt.%, about 0.2 to about 9 wt.%, about 0.2 to about

8 wt.%, about 0.2 to about 7 wt.%, about 0.2 to about 6 wt.%, about 0.2 to about 5 wt.%, about 0.2 to about 4 wt.%, about 0.2 to about 3 wt.%, about 0.2 to about 2 wt.%, about 0.2 to about 1 wt.%, about 0.5 to about 10 wt.%, about 0.5 to about 9 wt.%, about 0.5 to about 8 wt.%, about 0.5 to about 7 wt.%, about 0.5 to about 6 wt.%, about 0.5 to about 5 wt.%, about 0.5 to about 4 wt.%, about 0.5 to about 3 wt.%, about 0.5 to about 2 wt.%, about 0.5 to about 1 wt.%, about 1 to about 10 wt.%, about 1 to about 9 wt.%, about 1 to about 8 wt.%, about 1 to about 7 wt.%, about 1 to about 6 wt.%, about 1 to about 5 wt.%, about 1 to about 4 wt.%, about 1 to about 3 wt.%, about 1 to about 2 wt.%, about 2 to about 10 wt.%, about 2 to about

9 wt.%, about 2 to about 8 wt.%, about 2 to about 7 wt.%, about 2 to about 6 wt.%, about 2 to about 5 wt.%, about 2 to about 4 wt.%, about 2 to about 3 wt.%, about 4 to about 10 wt.%, about 4 to about 9 wt.%, about 4 to about 8 wt.%, about 4 to about 7 wt.%, about 4 to about 6 wt.%, or about 4 to about 5 wt.%, including ranges and subranges therebetween, based on the total weight of the cannabinoid composition.

[00068] In various embodiments, the cannabinoid compositions include one or more flavonoid(s) derived and/or found in the cannabis plant. As used herein, cannabis flavonoids refer to flavonoids that are found in the cannabis plant, regardless of whether the flavonoid(s) is extracted from a cannabis plant or are synthesized/manufactured by human activity. There are about 20 flavonoids in cannabis, including catechins and quercetin. In some embodiments, the cannabinoid composition may include cannabis flavonoids chosen from catechins, quercetin, and a mixture thereof.

[00069] Active ingredientfsl

[00070] The cannabinoid compositions may further include active ingredients, which may depend on the form of administering the cannabinoid compositions. For example, the cannabinoid compositions may include one or more of glycyrrhizin, phillyrin, phillygenin, ginseng, coconut oil, elderberry extract, olive leaf extract, eucalyptus, oregano oil, goldenseal root, n-acetylcysteine (NAC), probiotics, dnnamon, turmeric, ginger, green tea extract, chlorella, echinacea, vitamin D, vitamin C, garlic extract, rosemary oil, oregano oil, thyme oil, lemon balm, nicotinamide, cherry extract, or a mixture thereof.

[00071] The cannabinoid compositions may include one or more active ingredients that are a vitamin. Examples of vitamins that may be present in the cannabinoid compositions include, but are not limited to, vitamin Bl, vitamin B2, niadn, vitamin B6, vitamin B12, vitamin C, vitamin E, and inositol.

[00072] Additionally or alternatively, the active ingredients may include a plant extrad. Non-limiting examples of plant extracts that may be present in the cannabinoid composition include guarana extract, a black pepper extract, a maca extract, a ginseng extract, a cistanche extract, a kudzu root extract, a turmeric extract, a ginkgo extract, a wolfberry extract, an acai berry extract, a bilberry extract, a coconut extract, and/or a prunella vulgaris extract. In some cases, the active ingredients may be chosen from amino adds, such as is one or a combination of two or more selected from theanine, L-tyrosine, glydne, and glutamic acid. [00073] One of the foregoing active ingredients may be included in the cannabinoid compositions in an amount of about 0.1 to about 10 wt.% based on the total weight of the cannabinoid composition. In some instances, the amount of the active ingredient(s) present in the cannabinoid composition may be from about 0.1 to about 10 wt.%, about 0.1 to about 9 wt.%, about 0.1 to about 8 wt.%, about 0.1 to about 7 wt.%, about 0.1 to about 6 wt.%, about 0.1 to about 5 wt.%, about 0.1 to about 4 wt.%, about 0.1 to about 3 wt.%, about 0.1 to about 2 wt.%, about 0.1 to about 1 wt.%, about 0.2 to about 10 wt.%, about 0.2 to about 9 wt.%, about 0.2 to about 8 wt.%, about 0.2 to about 7 wt.%, about 0.2 to about 6 wt.%, about 0.2 to about 5 wt.%, about 0.2 to about 4 wt.%, about 0.2 to about 3 wt.%, about 0.2 to about 2 wt.%, about 0.2 to about 1 wt.%, about 0.5 to about 10 wt.%, about 0.5 to about 9 wt.%, about 0.5 to about 8 wt.%, about 0.5 to about 7 wt.%, about 0.5 to about 6 wt.%, about 0.5 to about 5 wt.%, about 0.5 to about 4 wt.%, about 0.5 to about 3 wt.%, about 0.5 to about 2 wt.%, about 0.5 to about 1 wt.%, about 1 to about 10 wt.%, about 1 to about 9 wt.%, about 1 to about 8 wt.%, about 1 to about 7 wt.%, about 1 to about 6 wt.%, about 1 to about 5 wt.%, about 1 to about 4 wt.%, about 1 to about 3 wt.%, about 1 to about 2 wt.%, about 2 to about 10 wt.%, about 2 to about 9 wt.%, about 2 to about 8 wt.%, about 2 to about 7 wt.%, about 2 to about 6 wt.%, about 2 to about 5 wt.%, about 2 to about 4 wt.%, about 2 to about 3 wt.%, about 4 to about 10 wt.%, about 4 to about 9 wt.%, about 4 to about 8 wt.%, about 4 to about 7 wt.%, about 4 to about 6 wt.%, or about 4 to about 5 wt.%, including ranges and subranges therebetween, based on the total weight of the cannabinoid composition.

[00074] Water

[00075] The cannabinoid composition may, in some embodiments, include 5 wt.% or more of water. For example, the amount of water present in the cannabinoid composition may be about 10 wt.% or more, about 15 wt.% or more, about 20 wt.% or more, about 25 wt.% or more, about 30 wt.% or more, about 35 wt.% or more, about 40 wt.% or more, 45 wt.% or more, 50 wt.% or more, about 55 wt.% or more, about 60 wt.% or more, about 65 wt.% or more, about 70 wt.% or more, about 75 wt.% or more, about 80 wt.% or more, about 85 wt.% or more, or about 90 wt.% or more based on the total weight of the cannabinoid composition. Additionally or alternatively, the cannabinoid compositions may have about 95 wt.% or less, about 90 wt.% or less, about 85 wt.% or less, about 80 wt.% or less, about 75 wt.% or less, about 70 wt.% or less, about 65 wt.% or less, about 60 wt.% or less, about 55 wt.% or less, about 50 wt.% or less, about 45 wt.% or less, about 40 wt.% or less, about 35 wt.% or less, about 30 wt.% or less, about 25 wt.% or less, about 20 wt.% or less, about 15 wt.% or less, about 10 wt.% or less, about 5 wt.% or less, about 3 wt.% or less, about 2 wt.% or less, or about 1 wt.% or less of water based on the total weight of the cannabinoid composition. In some embodiments, the cannabinoid compositions have an amount of water based on the aforementioned lower and upper limits, such as about 5 to about 95 wt.%, about 40 to about 90 wt.%, about 45 to about 80 wt.%, about 48 to about 75 wt.%, including ranges and subranges therebetween, based on the total weight of the cannabinoid composition. Although the cannabinoid compositions may be aqueous, certain embodiments of the cannabinoid compositions may be free of water (anhydrous) or substantially free of water (substantially anhydrous).

[00076] Exdpientfsl

[00077] The cannabinoid composition may include one or more exdpients(s) in an amount of about 1 to about 90 wt.% based on the total weight of the cannabinoid composition. In some instances, the amount of exdpients present in the cannabinoid composition may be from about 1 to about 90 wt.%, about 1 to about 80 wt.%, about 1 to about 70 wt.%, about 1 to about 60 wt.%, about 1 to about 55 wt.%, about 1 to about 50 wt.%, about 1 to about 45 wt.%, about 1 to about 40 wt.%, about 1 to about 35 wt.%, about 1 to about 30 wt.%, about 1 to about 25 wt.%, about 1 to about 20 wt.%, about 1 to about 15 wt.%, about 1 to about 10 wt.%, about 1 to about 5 wt.%, about 5 to about 90 wt.%, about 5 to about 80 wt.%, about 5 to about 70 wt.%, about 5 to about 60 wt.%, about 5 to about 55 wt.%, about 5 to about 50 wt.%, about 5 to about 45 wt.%, about 5 to about 40 wt.%, about 5 to about 35 wt.%, about 5 to about 30 wt.%, about 5 to about 25 wt.%, about 5 to about 20 wt.%, about 5 to about 55 wt.%, about 5 to about 10 wt.%, about 10 to about 90 wt.%, about 10 to about 80 wt.%, about 10 to about 70 wt.%, about 10 to about 60 wt.%, about 10 to about 55 wt.%, about 10 to about 50 wt.%, about 10 to about 45 wt.%, about 10 to about 40 wt.%, about 10 to about 35 wt.%, about 10 to about 30 wt.%, about 10 to about 25 wt.%, about 10 to about 20 wt.%, about 10 to about 15 wt.%, about 20 to about 90 wt.%, about 20 to about 80 wt.%, about 20 to about 70 wt.%, about 20 to about 60 wt.%, about 20 to about 55 wt.%, about 20 to about 50 wt.%, about 20 to about 45 wt.%, about 20 to about 40 wt.%, about 20 to about 35 wt.%, about 20 to about 30 wt.%, about 20 to about 25 wt.%, about 30 to about 90 wt.%, about 30 to about 80 wt.%, about 30 to about 70 wt.%, about 30 to about 60 wt.%, about 30 to about 55 wt.%, about 30 to about 50 wt.%, about 30 to about 45 wt.%, about 30 to about 40 wt.%, about 30 to about 35 wt.%, about 40 to about 90 wt.%, about 40 to about 80 wt.%, about 40 to about 70 wt.%, about 40 to about 60 wt.%, about 40 to about 55 wt.%, about 40 to about 50 wt.%, about 40 to about 45 wt.%, about 45 to about 55 wt.%, or about 45 to about 50 wt.%, including ranges and subranges therebetween, based on the total weight of the cannabinoid composition.

[00078] For example, one or more excipients may be included to assist in forming and/or stabilizing the composition, as well as the form of the cannabinoid composition for administration. Such excipients may include inactive excipients 114. Suitable excipients that may optionally be incorporated into the cannabinoid composition include, but are not limited to, flavorings, flavor modifiers, colorants, modifiers, fillers, preservatives, pH adjusting agents, buffering agents, disintegrants, dispersants, diluents, binders buffering agents, permeation enhancers, solubilizers, emulsifiers, surfactants, antioxidants, and sweeteners. The exdpients may be pharmaceutically acceptable excipients. The amount and types of excipients utilized to form pharmaceutical compositions may be selected according to known principles of pharmaceutical science.

[00079] In some embodiments, the exdpient may be a diluent. The diluent may be compressible ( e.g ., plastically deformable) or abrasively brittle. Non-limiting examples of suitable compressible diluents include microcrystalline cellulose (MCC), cellulose derivatives, cellulose powder, cellulose esters (e.g., acetate and butyrate mixed esters), ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, corn starch, phosphated corn starch, pregelatinized com starch, rice starch, potato starch, tapioca starch, starch-lactose, starch-calcium carbonate, sodium starch glycolate, glucose, fructose, lactose, ladose monohydrate, sucrose, xylose, lactitol, mannitol, malitol, sorbitol, xylitol, maltodextrin, and trehalose. Non-limiting examples of abrasively brittle diluents include dibasic calcium phosphate (anhydrous or dihydrate), caldum phosphate tribasic, calcium carbonate, and magnesium carbonate.

[00080] In some embodiments, the excipient may be a binder. Non-limiting examples of binders include, but are not limited to, starches, pregelatinized starches, gelatin, polyvinylpyrrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, C12-C18 fatty add alcohol, polyethylene glycol, polyols, and saccharides.

[00081] Various embodiments may include the excipient as a filler. Fillers generally serve to create desired bulk, flow properties, and compression characteristics in the preparation of tablets and capsule fillings. Suitable fillers include, but are not limited to, carbohydrates, inorganic compounds, and polyvinylpyrrolidone. By way of non-limiting example, the filler may be calcium sulfate, both di- and tri-basic, starch, caldum carbonate, magnesium carbonate, microcrystalline cellulose, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, talc, modified starches, lactose, sucrose, mannitol, or sorbitol. In some cases, the filler(s) is chosen from cellulose, modified cellulose (e.g., microcrystalline cellulose), cellulose ethers (e.g., hydroxypropylmethylcellulose (HPMC)), lactose, dextrose, and a mixture thereof. In some cases, the filler is microcrystalline cellulose.

[00082] In further embodiments, the exdpient may be a buffering agent. Representative examples of suitable buffering agents include, but are not limited to, phosphates, carbonates, dtrates, tris buffers, and buffered saline salts (e.g., Tris buffered saline or phosphate buffered saline).

[00083] In various embodiments, the exdpient may be a pH modifier. By way of non limiting example, the pH modifying agent may be sodium carbonate, sodium bicarbonate, sodium citrate, dtric add, or phosphoric add.

[00084] In various embodiments, the excipient may be a disintegrant. Disintegrants may serve to disintegrate tablets, granules, etc., and thus enhance dissolution of a solid dosage form upon contact with the liquid dissolution medium. The disintegrant may be non- effervescent or effervescent. Non-limiting examples of non-effervescent disintegrants include, but are not limited to, starches (e.g., com starch, potato starch, pregelatinized and modified starches thereof), sweeteners, clays (e.g., bentonite), micro-crystalline cellulose, alginates, sodium starch glycolate, and gums (e.g., agar, guar, locust bean, karaya, pecitin, and tragacanth). In some cases, the effervescent disintegrants include sodium bicarbonate in combination with citric add and sodium bicarbonate in combination with tartaric add. Additionally or alternatively, the disintegrants may be crospovidone (cross linked polyvinyl N-pyrrolidone), carboxymethylcellulose, salts and derivatives thereof. Crosslinked derivatives, for instance, may include croscarmellose sodium (cross-linked polymer of carboxymethylcellulose sodium) sodium carboxymethyl glycolate, sodium starch glycolate, carrageenan, agar, and pectin. In at least one instance, the disintegrant(s) is crospovidone and/or croscarmellose sodium.

[00085] In some embodiments, the exdpient may be a dispersant or dispersion-enhancing agent. Non-limiting examples of dispersants may include, but are not limited to, starch, alginic add, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose.

[00086] In further embodiments, the exdpient may be a preservative. Non-limiting examples of suitable preservatives include antioxidants, such as BHA, BHT, vitamin A, vitamin C, vitamin E, retinyl palmitate, citric acid, sodium dtrate, chelators such as EDTA or EGTA, and antimicrobials, such as parabens, chlorobutanol, or phenol.

[00087] In yet further embodiments, the exdpient may be a lubricant. Lubricants may serve to prevent sticking of ingredients to one another or to the capsule-filling or tablet compressing machines. Non-limiting examples of suitable lubricants include minerals (such as talc or silica) and fats (such as vegetable stearin, magnesium stearate, or stearic add).

Even though not strictly identical with glidants (which serve to reduce interparticular friction and thus enhance flowability of a particle mixture in the manufacture of tablets or capsules), glidants and lubricants are collectively referred to as lubricants herein. In some cases, a lubricant may be chosen from one or more of the following: stearic add, talc, stearin, silica, such as hydrophilic fumed silica or colloidal silica, starch, calcium phosphate (Ca ₃ (PO 4)2), calcium stearate, and aluminum stearate.

[00088] In various embodiments, the excipient may be a taste-masking agent. Taste- masking materials include cellulose ethers, polyethylene glycols, polyvinyl alcohol, polyvinyl alcohol, polyethylene glycol copolymers, monoglycerides, triglycerides, acrylic polymers, mixtures of acrylic polymers with cellulose ethers, cellulose acetate phthalate, and combinations thereof.

[00089] In further embodiments, the exdpient may be a flavoring agent. Flavoring agents may be chosen from synthetic flavor oils, flavoring aromatics, natural oils, extrads from plants, leaves, flowers, fruits, and combinations thereof.

[00090] In still further embodiments, the excipient may be a coloring agent. Non-limiting examples of color additives include, but are not limited to, food, drug and, cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C). [00091] The cannabinoid compositions may be formulated to be in a desired form depending on the method of administration. For instance, the cannabinoid compositions may be formulated to be aqueous ( e.g ., for administration as an oral spray) or anhydrous ( e.g ., for administration as a tablet). As noted herein, the cannabinoid compositions may be formulated to be in the form of an emulsion, an oral spray, a nasal spray, a nasal gel, a lozenge, a tablet, a chewable tablet, a capsule, a gummy candy, an oral strip, a powder, or the like. With reference to FIG. 1, forms 126 for the cannabinoid composition may depend upon preferences for personal use, administering use, dosage needs, etc. Forms may include but not be limited to lozenge 128, oral dissolvable strips 130, chewable tablet 132, oral spray 134, ingestible pill 136, gummy 138, oil drops 140, or others 142 (e.g., other types of tablet, pill, emulsion, effervescent powder, capsule, syrup, mouth rinse, powder, flavored powder, nasal spray, aerosol inhalable liquid, inhalable powder, transdermal cream, gel, patch, or suppository).

[00092] Lozenges 128 may be a small medicinal tablet, originally in the shape of a lozenge, taken for sore throats and dissolved in the mouth.

[00093] Oral dissolvable strips 130 may be fast-dissolving films, which may be designed to dissolve upon contact with a wet surface, such as the tongue, within a few seconds, which means the consumer can take the product without need for additional liquid. The convenience of an oral dissolvable strip 130 may provide both a marketing advantage and increased patient compliance. As certain ingredient may be directly absorbed into systemic circulation, degradation in gastrointestinal tract and first pass effect can be avoided.

[00094] Chewable tablets 132 are oral solid dosage forms which are intended to be chewed in the mouth prior to swallowing, and not intended to be swallowed intact. Oral spray 134 supplementation may provide an absorption rate approximately nine times greater than that of pills. Once the cannabinoid composition is sprayed into the mouth, the certain ingredients reach the bloodstream within minutes.

[00095] Ingestible pills 136 are used to take into the stomach by drawing through the throat and esophagus with a voluntary muscular action, as food, drink, or other substances to transfer ingredients into the gut. Gummy candies 138 have a pleasant taste and are easy to take. Oil drops 140 may be used to enhance a drink or for direct administration onto the tongue or eye.

[00096] There are many other forms 142 delivery mechanisms to deliver the composition. Solid dosage forms for oral administration may be contained in capsules, tablets, caplets, pills, powders, pellets, and granules. The cannabinoid composition may include various sweetening or flavoring agents, coloring agents, and emulsifying and/or suspending agents, as well as diluents such as water, ethanol, glycerin, and combinations thereof.

[00097] Transmucosal administration may be accomplished through the use of nasal sprays, aerosol sprays, tablets, or suppositories, and transdermal administration may be via ointments, salves, gels, patches, suspensions, or creams as generally known in the art. Non limiting examples of structured fluid delivery systems may include nanoparticles, liposomes, microemulsions, micelles, dendrimers, and other phospholipid-containing systems.

Methods of incorporating compositions into delivery vehicles are known in the art.

[00098] In further embodiments, a liposome delivery vehicle may be utilized. Liposomes may also be used for delivery of a cannabinoid composition. Generally, liposomes are spherical vesicles with a phospholipid bilayer membrane. The lipid bilayer of a liposome may fuse with other bilayers ( e.g ., the cell membrane), thus delivering the contents of the liposome to cells.

[00099] Liposomes may include a variety of different types of phosolipids having varying hydrocarbon chain lengths. Phospholipids generally include two fatty adds linked through glycerol phosphate to one of a variety of polar groups. Suitable phospholids include phosphatidic acid (PA), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), diphosphatidylglycerol (DPG), phosphatidylcholine (PC), and phosphatidylethanolamine (PE). The fatty acid chains included in the phospholipids may range from about 6 to about 26 carbon atoms in length, and the lipid chains may be saturated or unsaturated. Suitable fatty acid chains include (common name presented in parentheses) n-dodecanoate (laurate), n-tretradecanoate (myristate), n-hexadecanoate (palmitate), n-octadecanoate (stearate), n-eicosanoate (arachidate), n-docosanoate (behenate), n-tetracosanoate (lignocerate), cis-9-hexadecenoate (palmitoleate), ds-9- octadecanoate (oleate), cis,cis-9,12-octadecandienoate (linoleate), all ds-9, 12, 15- odadecatrienoate (linolenate), and all cis-5,8,ll,14-eicosatetraenoate (arachidonate). The two fatty add chains of a phospholipid may be identical or different. Acceptable phospholipids include dioleoyl PS, dioleoyl PC, distearoyl PS, distearoyl PC, dimyristoyl PS, dimyristoyl PC, dipalmitoyl PG, stearoyl, oleoyl PS, palmitoyl, linolenyl PS, and the like. [00100] The phospholipids may come from any natural source and as such, may include a mixture of phospholipids. For example, egg yolk is rich in PC, PG, and PE; soy beans contains PC, PE, PI, and PA; and animal brain or spinal cord is enriched in PS. Phospholipids may come from synthetic sources too. Mixtures of phospholipids having a varied ratio of individual phospholipids may be used. Mixtures of different phospholipids may result in liposome compositions having advantageous activity or stability of activity properties. The aforementioned phospholipids may be mixed in optimal ratios with cationic lipids, such as N-(l-(2,3-dioleolyoxy)propyl)-N,N,N-trimethyl ammonium chloride, 1,1'- dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchloarate, 3,3'- deheptyloxacarbocyanine iodide, l,l'-dedodecyl-3,3,3',3'- tetramethylindocarbocyanine perchloarate, l,l'-dioleyl-3,3,3',3'-tetramethylindo carbocyanine methanesulfonate, N-4- (delinoleylaminostyryl)-N-methylpyridinium iodide, or l,l,-dilinoleyl-3,3,3',3'- tetramethylindocarbocyanine perchloarate.

[00101] Liposomes may optionally include sphingolipids— in which spingosine is the structural counterpart of glycerol and one of the fatty acids of a phosphoglyceride— or cholesterol, a major component of animal cell membranes. Liposomes may optionally contain pegylated lipids, which are lipids covalently linked to polymers of polyethylene glycol (PEG). PEGs may range in size from about 500 to about 10,000 daltons. Liposomes may further include a suitable solvent. The solvent may be an organic solvent or an inorganic solvent. Suitable solvents include, but are not limited to, dimethylsulfoxide (DMSO), methylpyrrolidone, N-methylpyrrolidone, acetronitrile, alcohols, dimethylformamide, tetrahydrofuran, or combinations thereof.

[00102] Liposomes carrying a cannabinoid composition may be prepared by any known method of preparing liposomes for drug delivery, such as detailed in U.S. Pat. Nos. 4,241,046, 4,394,448, 4,529,561, 4,755,388, 4,828,837, 4,925,661, 4,954,345, 4,957,735, 5,043,164, 5,064,655, 5,077,211, and 5,264,618, the disclosures of which are hereby incorporated by reference. For example, liposomes may be prepared by sonicating lipids in an aqueous solution, solvent injection, lipid hydration, reverse evaporation, or freeze drying by repeated freezing and thawing. In some embodiments, the liposomes are formed by sonication. The liposomes may be multilamellar, which have many layers like an onion, or unilamellar. The liposomes may be large or small. Continued high-shear sonication tends to form smaller unilamellar lipsomes.

[00103] In various embodiments, each of the parameters that govern liposome formation may be varied. These parameters include, but are not limited to, temperature, pH, concentration of methionine compound, concentration, composition of lipid, concentration of multivalent cations, rate of mixing, and presence of and concentration of solvent.

[00104] The cannabinoid composition may be formulated as part of a microemulsion. Microemulsions are generally clear, thermodynamically stable solutions that include an aqueous solution, a surfactant, and oil. The oil in this case, is the supercritical fluid phase. The surfactant rests at the oil-water interface. Any of a variety of surfactants are suitable for use in microemulsion formulations, including those described herein or otherwise known in the art. The aqueous microdomains suitable for use in the disclosure generally may have characteristic structural dimensions from about 5 nm to about 100 nm. Aggregates of this size are poor scatterers of visible light, and hence, these solutions are optically clear. In various embodiments, microemulsions can have a multitude of different microscopic structures, including sphere, rod, or disc shaped aggregates. In some embodiments, the structure may be micelles, which are the simplest microemulsion structures that are generally spherical or cylindrical objects. Micelles may be similar to drops of oil in water, and reverse micelles may be similar to drops of water in oil. In some embodiments, the microemulsion structure is the lamellae and may include consecutive layers of water and oil separated by layers of surfactant. The oil of microemulsions optimally includes phospholipids. Any of the phospholipids detailed above for liposomes are suitable for embodiments directed to microemulsions. A composition including at least one anti-viral therapeutic derivative may be encapsulated in a microemulsion by any method generally known in the art.

[00105] The cannabinoid composition may be formulated as a tablet or a capsule. The tablet or capsule may be an immediate release composition. In some embodiments, the cannabinoid composition is in the form of a capsule or tablet that is characterized by a disintegration time of 30 minutes or less, such as 20 minutes or less, 15 minutes or less, or 10 minutes or less. The disintegration time referred to above is measured in 0.01 N HC1 at 37°C.

[00106] The cannabinoid composition may be a powder contained in a capsule. The capsule itself may be any pharmaceutically acceptable capsule ( e.g ., a hard gelatin capsule), but may be easily dissolvable. In cases where the cannabinoid composition is in the form of a powder and contained in a capsule, the weight percentages of the cannabinoid composition does not include the weight of capsule.

[00107] Various embodiments include use of such cannabinoid compositions in administration methods for alleviating viral symptoms, reducing viral replication, suppress inflammation, and/or improving an immune response to viral infections. Viral symptoms may refer to one or more of fever, sore throat, headache, cough, aches and pains, sneezing, rash, nasal congestion, runny nose, and the like. The methods may include the administration of an amount and form of a cannabinoid composition to an individual in need thereof. In various embodiments, a therapeutically effective amount of the cannabinoid composition is administered to the individual. As used herein "therapeutically effective amount" or "therapeutically effective dosage" refers to an amount that is effective to achieve a desired therapeutic result. In some embodiments, the desired therapeutic result is a reduction of viral symptoms.

[00108] In some cases, the methods may include administering an amount of the cannabinoid composition to provide a dose of about 1 to about 60 mg of one or more cannabinoid(s), a dose of about 1 to about 75 mg of zinc compound(s), about 1 to about 30 mg of terpene(s), and/or a dose of about 50 to 400 mg of active ingredients. For instance, the method may include administering a dose of cannabinoid(s) of about 1 to about 60 mg, about 1 to about 50 mg, about 1 to about 40 mg, about 1 to about 30 mg, about 1 to about 20 mg, about 5 to about 60 mg, about 5 to about 50 mg, about 5 to about 40 mg, about 5 to about 30 mg, about 5 to about 20 mg, about 10 to about 60 mg, about 10 to about 50 mg, about 10 to about 40 mg, about 10 to about 30 mg, about 10 to about 20 mg, about 10 to about 60 mg, about 20 to about 60 mg, about 30 to about 60 mg, about 40 to about 60 mg, about 50 to about 60 mg, about 1 to about 60 mg, about 10 to about 50 mg, about 20 to about 40 mg, or about 20 to about 30 mg, including any ranges or subranges therebetween.

[00109] The methods may include administering a dose of CBG of about 1 to about 6 mg, about 1 to about 5 mg, about 1 to about 4 mg, about 1 to about 3 mg, about 1 to about 2 mg, about 2 to about 6 mg, about 2 to about 5 mg, about 2 to about 4 mg, about 4 to about 6 mg, or about 5 to about 6 mg, including any ranges or subranges therebetween. Additionally or alternatively, the method may include administering a dose of CBD of about 1 to about 60 mg, about 1 to about 50 mg, about 1 to about 40 mg, about 1 to about 30 mg, about 1 to about 20 mg, about 5 to about 60 mg, about 5 to about 50 mg, about 5 to about 40 mg, about 5 to about 30 mg, about 5 to about 20 mg, about 10 to about 60 mg, about 10 to about 50 mg, about 10 to about 40 mg, about 10 to about 30 mg, about 10 to about 20 mg, about 10 to about 60 mg, about 20 to about 60 mg, about 30 to about 60 mg, about 40 to about 60 mg, about 50 to about 60 mg, about 1 to about 60 mg, about 10 to about 50 mg, about 20 to about 40 mg, or about 20 to about 30 mg, including any ranges or subranges therebetween.

[00110] The methods may include administering a dose of zinc compound(s) of about 1 to about 75 mg, about 1 to about 60 mg, about 1 to about 50 mg, about 1 to about 40 mg, about 1 to about 30 mg, about 1 to about 20 mg, about 5 to about 60 mg, about 5 to about 50 mg, about 5 to about 40 mg, about 5 to about 30 mg, about 5 to about 20 mg, about 10 to about 60 mg, about 10 to about 50 mg, about 10 to about 40 mg, about 10 to about 30 mg, about 10 to about 20 mg, about 10 to about 75 mg, about 20 to about 75 mg, about 30 to about 75 mg, about 40 to about 75 mg, about 50 to about 75 mg, about 1 to about 60 mg, about 10 to about 50 mg, about 20 to about 40 mg, or about 20 to about 30 mg, including any ranges or subranges therebetween.

[00111] The methods may include administering a dose of terpenes of about 1 to about 30 mg, about 1 to about 20 mg, about 5 to about 30 mg, about 5 to about 20 mg, about 10 to about 60 mg, about 10 to about 50 mg, about 10 to about 40 mg, or about 10 to about 30 mg, including any ranges or subranges therebetween.

[00112] The methods may include administering a dose of active ingredients of about 50 to about 400 mg, about 100 to about 300 mg, about 150 to about 250 mg; about 100 to about 400 mg, about 150 to about 400 mg, about 200 to about 400 mg, about 250 to about 400 mg, about 300 to about 400 mg; about 50 to about 350 mg, about 50 to about 300 mg, about 50 to about 250 mg, about 50 to about 200 mg, or about 50 to about 150 mg, including any ranges or subranges therebetween.

[00113] Further embodiments of the disclosure may provide cannabinoid recommendation system 116 for assessing whether the cannabinoid compositions should be administered to an individual and, optionally, recommending to the individual or a medical professional whether a particular cannabinoid composition should be administered and in what dosage and/or form. Cannabinoid recommendation system 116 may include diagnostic module 118, choosing composition module 120, administration module 122, and monitoring module 124. [00114] While illustrated as being assodated with the carmabinoid recommendation system 116 in FIG. 1, the modules 118-124 may be part of one or more computer systems suitable for use with embodiments of the present invention and are thus intended to represent a broad category of such computer components that are well-known in the art. Thus, the computer systems in which each module may reside can be a personal computer, hand held computing device, telephone, mobile computing device, workstation, server, minicomputer, mainframe computer, or any other computing device. The computer system(s) associated with the modules 118-124 can also include different bus configurations, networked platforms, multi-processor platforms, etc., The computer system may include computer components known in the art, including memory and other storage devices, processors, input devices, output devices, display devices, and peripheral devices. The modules 118-124 may include instructions stored in memory or a storage device and executable by the processor to perform assodated functions, which may be based on input received via input devices and results of which may be output via output devices.

[00115] FIG. 3 is a flowchart illustrating exemplary steps of a method of preparing a cannabinoid composition for a user and assodated modules. In step 310, the diagnostic module 118 may be executed to assess whether the virus treatment composition is recommended for use, as well as recommended frequency and dosage regimens. In various instances, there may be published reports of viruses such as COVID-19 reaching a specific geolocation area in what would be considered to the individual or government a risk geolocation. If a risk geolocation appears, execution of the diagnostic module 118 may include performing an assessment of the individual and/or instrud such an individual to start taking a preventive use dose in the form of a tablet, gummy bear, lozenge, etc.

[00116] In various embodiments, the diagnostic module 118 may obtain and use published reports regarding symptoms of viruses such as COVID-19 to assess whether an individual's provided symptoms appear to match. If an individual appears to have any of those symptoms, the diagnostic module 118 may assess and/or instruct the individual to start administering a recommended dosage of a cannabinoid composition associated with the identified symptoms. In various embodiments, the individual can take a viral test, such as the COVID-19 test and enter the results into the diagnostic module 118. The diagnostic module 118 may then further use such feedback to assess and/or instruct the individual to start taking a dosage, e.g. _r such as in the form of a tablet, gummy bear, lozenges, etc. The individual may continue to input updated symptoms and status thereof over time, and the diagnostic module 118 may recommend different dosages or compositions in response to such symptom data.

[00117] The cannabinoid recommendation system 116 may include a choosing composition module 120, which is executable for selecting an appropriate dosage and form for the virus treatment composition. In step 320, the choosing composition module 120 may be executed to choose a form for the individual. For instance, some individuals may easily adopt to a gummy bear candy, whereas others may prefer a lozenge 128. Others that want high efficacy might be recommended the oral spray or the tablet form.

[00118] The cannabinoid recommendation system 116 may further be associated with an administering module 122. In step 330, the administering module 122 may be controlled or otherwise receive prescription or control data from a doctor that has evaluated the symptoms and provided a recommendation regarding the dosage of the cannabinoid composition or one or more ingredients therein. The administering module 122 may receive an assessment or input from a pharmacist, school nurse, doctor, or the like. Such instructions or data may be received and reconciled by the administering module 112 with the recommendations of the diagnostic module 118. The administering module 112 may therefore provide specific administration instructions to the requesting individual via a display of a user device.

[00119] In step 340, the monitoring module 124 may be used to monitor the progress of the use of the virus treatment composition. The monitoring module 124 may include any sensor or device that measures the effects of having a virus, such as temperature sensor, blood oxygen levels, and/or sweat bands. The monitoring module 124 include a device for receiving an input regarding the subjective scale of pain of the individual. The monitoring module 124 may be measuring the blood oxygen of an individual. The monitoring module 124 may receive an input from a health care provider, doctor, and/or nurse regarding the individual. The monitoring module 124 is used to monitor the progress of the use of the virus treatment composition and form.

[00120] There may be feedback between the diagnostic module 118 to provide real time results, the composition, and form choice. For example, there might be no change if the results are satisfactory. In some instances, the form may change if the individual cannot adopt the starting form. The dose may increase if the results are not as adequate as needed, or the dose may decrease as the symptoms become alleviated. The dose may also stay the same for a given period of time after the symptoms are alleviated to insure the permanence of the alleviated results.

[00121] In some embodiments, an individual in need of treatment for and/or prevention from an ailment is diagnosed. In some embodiments, diagnosis of the need for treatment and / or prevention may be performed by a licensed medical practitioner. In some embodiments, diagnosis of the need for treatment and/or prevention may be performed by the individual. The composition deemed best suited for the treatment and/or prevention is selected at step 320 by execution of the choosing composition module 120.

[00122] In some embodiments, a cannabinoid composition may be provided that include at least one cannabinoid, at least one zinc compound, and at least one terpene. According to some embodiments, a cannabinoid composition is provided that include at least one cannabinoid and at least one zinc compound, and at least one zinc ionophore. According to some embodiments, a composition is provided that include at least one cannabinoid, at least one zinc compound, at least one terpene and at least one zinc ionophore. The activity of the cannabinoid compositions may be enhanced when at least one cannabinoid is combined with at least one zinc compound, at least one terpene and at least one zinc ionophore due to synergistic or additive effects between the individual components. According to some embodiments, at least one cannabinoid is selected from the group consisting of CBD, THC, CBC, CBG, CBN, CBL, CBDV, THCV and combinations thereof.

[00123] In some embodiments, a composition may include at least one cannabinoid, at least one terpene, at least one zinc compound and at least one zinc ionophore selected from the group consisting of hinokitol, hydroxychloroquine, quercetin, epigallocatechin, pyrithione and zincophorin.

[00124] In some embodiments, a composition may include at least one cannabinoid, at least one terpene, at least one zinc compound and at least one non-cannabinoid, non-terpene botanical substance selected from the group consisting of glycyrrhizin, phillyrin, phillygenin, ginseng, coconut oil, elderberry extract, olive leaf extract, eucalyptus, oregano oil, Goldenseal Root, probiotics, cinnamon, turmeric, ginger, green tea extract, chlorella, echinacea, vitamin D, garlic extract, rosemary oil, oregano oil, thyme oil.

[00125] In some embodiments, a cannabinoid composition includes additional ingredients selected from the group consisting of flavorings, flavor modifiers, colorants, modifiers, fillers, preservatives, pH adjusting agents, buffering agents, permeation enhancers, solubilizers, emulsifiers, surfactants, antioxidants, sweeteners.

[00126] Dosage forms of the disclosure may include amounts of individual components in the compositions. In some embodiments, the cannabinoid compositions may include an amount from about 0.001% to 10% of the total weight of a composition of the present disclosure. In some embodiments, the composition may contain 0.1% to 3 wt.% of cannabinoid components depending on the dosage form.

[00127] A preventive or use dose may be 1 gummy per day, an onset dose may be 2-4 gummies/day, and an enhanced dose may be 5-6 gummies/day. In some embodiments, the ionic zinc component may include an amount (as the salt equivalent) from about 0.1% to about 40 wt.% of the total weight of a cannabinoid composition of the present disclosure. In one embodiments, the cannabinoid composition may contain about 0.5 wt.% to about 30 wt.% of zinc ion (as the salt equivalent).

[00128] In some embodiments, the terpene component may include an amount from about 0.01 wt.% to about 10 wt.% of the total weight of a cannabinoid composition. In some embodiments, the cannabinoid composition may contain 0.1% to 3% of terpene components depending on the dosage form.

[00129] In some embodiments, the weight ratio of zinc ionophores to a zinc compound may be from about 3:1 to about 1:10. In various embodiments, the weight ratio of zinc ionophore to a zinc compound may be about 1:3.

[00130] In some embodiments, the preventive dose of a cannabinoid composition may include 1 to 10 mg cannabinoid, 1 to 15 mg of zinc, and 1 to 15 mg of terpenes and/or 1 to 300 mg of plant extracts and/or 1 to 100 mg vitamins. Embodiments may include dosage forms with a preventative dose of 10 to 20 mg of cannabinoid and 5 to 20 mg of zinc. Preventative dose may refer to the smallest amount of any ingredient/component that may prevent occurrence of symptoms of a disease.

[00131] The onset dose of a composition may include 1 to 100 mg cannabinoid and 1 to 75 mg of zinc with additional 1 to 100 mg of terpenes and/or 1 to 1500 mg of plant extracts and/or 1 to 1000 mg of vitamins. In some embodiments, the onset dosage is 40 to 60 mg of cannabinoid and 50 to 75 mg of zinc. Onset dose may refer to the amount of any ingredient/component to be consumed at the first appearance of the signs or symptoms of an illness.

[00132] In various embodiments, the functions performed in the processes and methods may be implemented in differing order. Furthermore, the outlined steps and operations are only provided as examples, and some of the steps and operations may be optional, combined into fewer steps and operations, or expanded into additional steps and operations without detracting from the essence of the disclosed embodiments.

[00133] In some embodiments, the cannabinoid compositions provided in the present disclosure may be used for treatment against severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus infection, idiopathic fibrosis, a-1 antitrypsin deficiency, asthma, airway hypersensitivity, seasonal allergy, bronchiectasis, chronic bronchitis, emphysema, and for the treatment of respiratory (e.g. lung) diseases such as chronic obstructive pulmonary disease, cystic fibroma, and viral infections (including but not limited to severe acute respiratory syndrome coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, rhinovirus, adenovirus, metapneumovirus, coxakey virus, echovirus, coronavirus, herpes virus, cytomegalovirus, etc.

[00134] In some embodiments, the cannabinoid compositions may be used for treatment of bacterial infections, including but not limited to Streptococcus pneumoniae, Staphylococcus aureus, Pneumococcus, Burkholderia ssp, Streptococcus Galactie, Haemophilus influenza, Haemophilus parainfluenza, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Moraxella catarrhalis, Chlamydophila pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila, Serratia marcescens, Serratia marceschumai Cis, Bordetella pertussis, etc.

[00135] In some embodiments, the cannabinoid compositions may be used for treatment of fungal infections including but not limited to Histoplasma capsatum, Cryptococcus neoformans, Pneumocystis irobechi, Cocddioides imimitis, etc. or parasitic infections, including but not limited to Toxoplasma gondii, Stromboloides stelcoralis, etc.), or environmental allergens and irritants, including but not limited toeg pollen and cat dander. [00136] In some embodiments, the cannabinoid compositions in the present disclosure may be used for the treatment and / or prevention of acute exacerbations of chronic diseases, such as exacerbations induced by aeroallergens such as amphiphilic particulates, and they may be administered to a subject in need thereof.

[00137] In some embodiments, the cannabinoid compositions of the present disclosure may be used to treat infectious respiratory diseases such as pneumonia (communicable pneumonia, nosocomial pneumonia, hospital-infected pneumonia, HAP, medical-related pneumonia, HCAP, ventilator- associated pneumonia (VAP)), ventilator-related tracheobronchitis (VAT), bronchitis, croups ( e.g ., post-intubation croup and infectious croup), tuberculosis, influenza, colds, and other viral infections (e.g., influenza virus, para Influenza virus, respiratory syncytial virus, rhinovirus, adenovirus, metapneumovirus, coxakey virus, echovirus, coronavirus, herpesvirus, cytomegalovirus, etc., bacterial infection (e.g., Streptococcus commonly called pneumococcus), New Monnier, Staffy Coccus aureus, Streptococcus agaractie, Haemophilus influenza, Hemophilus parainfluenza, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Moraxella catarrhalis, Chlamydophila pneumoniae, Mycoplasma pneumoniae mare Mycobacterium tuberculosis, Bordetella pertussis, etc.), fungal infections (e.g., Histoplasma capsatum, Cryptococcus neoformans, Pneumocystis irobechi, Cocddioides imimitis, etc.) or parasitic infections (e.g., Toxoplasma gondii, Strongiloy Des. Stealcolaris, etc.) or environmental allergens preliminary stimulants (e.g., aero allergen, such as airborne particulates) can be for treatment and / or prevention and/ or reduction of contagion of administering to a subject in need thereof.

[00138] In some embodiments, the cannabinoid compositions of the present disclosure may be used for the treatment or prevention of cardiovascular disease, autoimmune disorders, transplant rejection, autoimmune disorders, allergic asthma, infections and cancer. For example, the present disclosure includes treatment for postmenopausal osteoporosis, cryopyrin-related periodic syndrome (CAPS), paroxysmal nocturnal hemoglobinuria, psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and macular degeneration.

[00139] In some embodiments, the cannabinoid compositions of the present disclosure may be used for the treatment or prevention of spasms, anxiety / depression, inflammation, cancer, rheumatoid arthritis, multiple sclerosis, epilepsy, especially refractory epilepsy, and the use of antiviral drugs or analgesics.

[00140] In some embodiments, the cannabinoid compositions of present disclosure may be used in the preparation of a health supplement that enhances immunity, assists in lowering blood glucose / lipids, aids in improving memory, clears throat, improves sleep, loses weight, or improves chemical liver damage in the use of.

[00141] In some embodiments, the cannabinoid compositions of the present disclosure may be used as an over-the-counter consumer product for the treatment and prevention of viral infection.

[00142] FIG. 4 is a table of exemplary forms in which the cannabinoid composition may be provided. Forms for the virus mitigation composition may depend upon personal use, administering use, dosage needs, etc. Lozenges 410 are small medicinal tablets, originally in the shape of a lozenge, taken for sore throats, and dissolved in the mouth. For example, the lozenges 410 may have certain layers of ingredients of the composition, from other inactive ingredients on the outside to CBD/CBG/terpenes/other actives in an inner layer and zinc in the innermost layer. Of course, the compositions can be mixed in a powder and distribute amongst the entire lozenges 410.

[00143] Chewable tablets 420 are oral solid dosage form which is intended to be chewed in the mouth prior to swallowing and not intended to be swallowed intact. For example, the chewable tablets 420 may have certain layers of ingredients of the composition, from other inactive ingredients on the outside, to CBD/CBG/terpenes/other actives in an inner layer and zinc in the innermost layer. The compositions can be mixed in a powder and distribute amongst the entire chewable tablets 420.

[00144] Ingestible pills or capsules 430 are used to take through the throat and esophagus with a voluntary muscular action, as food, drink, or other substances to transfer active ingredients into the gut. For example, the ingestible pills, capsules, or tablets 430 may have certain layers of ingredients of the composition, from other inactive ingredients on the outside, to CBD/CBG/Terpenes/other actives in an inner layer and zinc in the innermost layer. The compositions can be mixed in a powder and distribute amongst the entire ingestible pill 430.

[00145] Oil drops 440 may be used to enhance a drink, as well as applied directly on the tongue or eye. For example, the oil drop 440 would have the compositions can be mixed in an oil drop form 440. Oral dissolvable strips 450 are fast dissolving films which are designed to dissolve upon contact with a wet surface, such as the tongue, within a few seconds, which means the consumer can take the product without need for additional liquid. This convenience of an oral dissolvable strips 450 provides both a marketing advantage and increased patient compliance. As the active ingredient is directly absorbed into systemic circulation, degradation in gastrointestinal tract and first pass effect can be avoided. For example, the oral dissolvable strips 450 may include the compositions as mixed in an oral dissolvable form.

[00146] Oral spray 460 supplementation provides an absorption rate approximately nine times greater than that of pills. Once the formula is sprayed into the mouth, the actives reach the bloodstream within minutes. No fillers or binders may be added, and the body may receive only pure ingredients. For example, the oral spray 430 has the compositions can be mixed in an oral spray form.

[00147] Gummy vitamins 470 have a pleasant taste and are easy to take. However, most varieties contain added sugars and may not list nutrient content accurately on their labels. For example, the gummy may have certain layers of ingredients of the composition, from other inactive ingredients on the outside, to CBD/CBG/Terpenes in an inner layer and Zinc in the innermost layer. Of course, the compositions can be mixed as a powder and distributed within a gummy form 470. There are many other forms 480 that can be taken orally, for instance, a sinus like form, a hard candy form, etc.

[00148] The terms "comprising," "having," and "including" are used in their open, non limiting sense. The terms "a" and "the" are understood to encompass the plural as well as the singular. The compositions and methods of the present disclosure can comprise, consist of, or consist essentially of the essential elements and limitations of the disclosure described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful.

[00149] All percentages, parts and ratios herein are based upon the total weight of the compositions of the present disclosure, unless otherwise indicated. All ranges and values disclosed herein are inclusive and combinable. The expression "inclusive" for a range of concentrations means that the limits of the range are included in the defined interval. For examples, any value or point described herein that falls within a range described herein can serve as a minimum or maximum value to derive a sub-range, etc. Furthermore, all ranges provided are meant to include every specific range within, and combination of sub ranges between, the given ranges. Thus, a range from 1-5, includes specifically 1, 2, 3, 4 and 5, as well as sub ranges such as 2-5, 3-5, 2-3, 2-4, 1-4, etc.

[00150] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients and/or reaction conditions are to be understood as being modified in all instances by the term "about," meaning within +/- 5% of the indicated number.

[00151] As used herein, the expression "at least one" is interchangeable with the expression "one or more" and thus includes individual components as well as mixtures/combinations.

[00152] The term "substantially free" or "essentially free" as used herein means that there is less than about 5% by weight of a specific material added to a composition based on the total weight of the compositions. Nonetheless, the compositions may include less than about 2 wt.%, less than about 1 wt.%, less than about 0.5 wt.%, less than about 0.1 wt.%, less than 0.01 wt.%, or none of the specified material.

[00153] The term "active material" as used herein with respect to the percent amount of an ingredient or raw material, refers to 100% activity of the ingredient or raw material. [00154] Throughout the disclosure, the term "a mixture thereof" may be used following a list of elements as shown in the following example where letters A-F represent the elements: "one or more elements selected from the group consisting of A, B, C, D, E, F, and a mixture thereof." The term, "a mixture thereof" does not require that the mixture include all of A, B, C, D, E, and F (although all of A, B, C, D, E, and F may be included). Rather, it indicates that a mixture of any two or more of A, B, C, D, E, and F can be included. In other words, it is equivalent to the phrase "one or more elements selected from the group consisting of A, B,

C, D, E, F, and a mixture of any two or more of A, B, C, D, E, and F."

[00155] Likewise, the term "a salt thereof" also relates to "salts thereof." Thus, where the disclosure refers to "an element selected from the group consisting of A, B, C, D, E, F, a salt thereof, and a mixture thereof," it indicates that that one or more of A, B, C, D, and F may be included, one or more of a salt of A, a salt of B, a salt of C, a salt of D, a salt of E, and a salt of F may be included, or a mixture of any two of A, B, C, D, E, F, a salt of A, a salt of B, a salt of C, a salt of D, a salt of E, and a salt of F may be included. The salts referred to throughout the disclosure may include salts having a counter-ion such as an alkali metal, alkaline earth metal, or ammonium counter-ion. This list of counter-ions, however, is non-limiting.

[00156] "Volatile", as used herein, means having a flash point of less than about 100 ^S C. "Non-volatile", as used herein, means having a flash point of greater than about 100 ^S C. [00157] The term "polymers," as defined herein, include homopolymers and copolymers formed from at least two different types of monomers.

[00158] All components and elements positively set forth in this disclosure can be negatively excluded from the claims. In other words, the compositions of the instant disclosure can be free or essentially free of all components and elements positively redted throughout the instant disclosure.

[00159] Some of the various categories of components identified may overlap. In such cases where overlap may exist and the composition includes both components (or the composition includes more than two components that overlap), an overlapping compound does not represent more than one component.

[00160] All publications and patent applications dted in this spedfication are herein incorporated by reference, and for any and all purposes, as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. In the event of an inconsistency between the present disclosure and any publications or patent application incorporated herein by reference, the present disclosure controls.

EXAMPLES

[00161] Implementation of the present disclosure is provided by way of the following examples. The examples serve to illustrate the technology without being limiting in nature.

Example 1

[00162] A cannabinoid composition (Example Composition 1) was prepared in accordance with the following formula. Example Composition 1 was an emulsion and met the following criteria: Dose size of 0.5 mL, CBD dose of 10 mg, Zinc dose of 10 mg.

Example Composition 1

Component % by weight CBD isolate 2.1%

Solubilizer 4.1%

Emulsifier 2.2%

Water 73.3%

Surfactant 0.9%

Antioxidant 0.8%

Preservatives 0.1%

Buffering agent 0.1%

Sweetener 0.9% pH adjustment/buffer 0.1%

Zinc gluconate 14.3%

Flavor 0.5% b-caryophyllene 0.5%

Flavor modifier 0.5%

[00163] Example Composition 1 may prospectively be used in a form of an oral spray to deliver 2 mg of CBD, 2 mg of zinc, and 0.5 mg of b-caryophyllene per spray. A preventive dose may be between 5 and 10 sprays per day, and an onset dose may be about 20 sprays per day.

Example 2

[00164] A cannabinoid composition (Example Composition 2) was prepared in accordance with the following formula. Example Composition 2 was an emulsion and met the following criteria: Dose size of 0.5 mL, CBD dose of 5 mg, CBG dose of 5 mg, and Zinc dose of 10 mg.

Example Composition 2

Component % by weight

CBD isolate 1.1%

CBG isolate 1.1%

Solubilizer 4.1%

Emulsifier 2.2%

Water 73.1%

Surfactant 0.9% Antioxidant 0.8%

Preservatives 0.1%

Buffering agent 0.1%

Sweetener 0.9% pH adjustment/buffer 0.1%

Zinc gluconate 14.3%

Flavor 0.5% b-caryophyllene 0.5%

Flavor modifier 0.5%

[00165] Example Composition 2 may prospectively be used in the form of an oral spray to deliver 1 mg of CBD, 1 mg of CBG, 0.5 mg of b-caryophyllene, and 2 mg of zinc per spray. The preventive dose may be 5 to 10 sprays per day, while the onset dose may be about 20 sprays/day.

Example 3

[00166] A cannabinoid composition (Example Composition 3) was prepared in accordance with the following formula. Example Composition 3 was an emulsion and met the following criteria: Dose size of 0.5 mL, CBG dose of 10 mg, and Zinc dose of 10 mg.

Example Composition 3

Component % by weight

CBG isolate 2.1%

Solubilizer 4.1%

Emulsifier 2.2%

Water 73.1%

Surfactant 0.9%

Antioxidant 0.8%

Preservatives 0.1%

Buffering agent 0.1%

Sweetener 0.9% pH adjustment/buffer 0.1%

Zinc gluconate 14.3%

Flavor 0.5% b-caryophyllene 0.5%

Flavor modifier 0.5%

[00167] Example Composition 3 may prospectively use in a form of an oral spray delivering 2 mg of CBG, 0.5 mg of b-caryophyllene, and 2 mg of zinc per spray. The preventive dose may be to 10 sprays per day, and the onset dose may be about 20 sprays/day.

Example 4

[00168] A cannabinoid composition (Example Composition 4) was prepared in accordance with the following formula. Example Composition 3 was in the form of a lozenge and met the following criteria: unit/dose size of 0.5 gram, CBD dose of 10 mg, and Zinc dose of 14 mg.

Example Composition 4

Component % by weight

Emulsifier 1.8%

Solubilizer 1.7%

CBD isolate 0.2% sugar 44.1% sweetener 37.5% zinc dtrate encapsulated 1.3%

Water 13.1% flavoring agent 0.4% color 0.01%

[00169] The preventive or use dosage may be 1 lozenge per day. The onset dosage may be 2 to 4 lozenges per day. In some cases, a user may be administered 5 lozenges per day.

Example 5

[00170] A cannabinoid composition (Example Composition 5) was prepared in accordance with the following formula. Example Composition 5 was a lozenge and met the following criteria: Unit/Dose size of 2.5 g, CBD dose of 10 mg, CBG dose of 2.5 mg, Zinc dose of 10 mg, and Terpene dose of 5 mg.

Example Composition 5 Component % by weight

Troche base 84.7% Solubilizer 2.5% CBD isolate 0.4% CBG isolate 0.2% Zinc dtrate 2.1% Terpenes 0.2% Color 0.02%

Water 9.8%

[00171] The recommended preventive or use dose 1 lozenges per day, onset dose 2-4 lozenges/day, enhanced dose 5 lozenges/day.

Example 6

[00172] A carmabinoid composition (Example Composition 6) was prepared in accordance with the following formula. Example Composition 6 was in the form of a tablet and met the following criteria: Unit/Dose size of 0.18 g, CBD dose of 5 mg, CBG dose of 5 mg, Zinc dose of 15 mg, and Antioxidant dose of 18 mg.

Example Composition 6

Component % by weight

CBD isolate 3.2%

CBG isolate 3.2%

Zinc dtrate 26.3%

Extract from berries (Betaberries) 10.0%

Sucralose 0.5% flavor modifier 0.8%

Lubricant 10.0%

Mannitol 20.8%

Binder 20.2%

Glidant 5.0%

[00173] Example Composition 6 may be administered at a preventive dose of 1 tablet per day, an onset dose of 2 to 4 tablets per day, and/or an enhanced dose 5 tablets per day. Example 7

[00174] A carmabinoid composition (Example Composition 7) was prepared in accordance with the following formula. Example Composition 7 was in the form of a chewable tablet and met the following criteria: Unit/dose amount of 4 g, CBD dose of 10 mg/tablet, CBG dose of 1 mg/tablet, Zinc dose of 15 mg/tablet, and Terpenes dose of 15 mg/tablet.

Example Composition 7

Component % by weight CBD isolate 0.3% CBG isolate 0.03% Zinc dtrate 1.2% terpenes 0.4% sweetener 0.1% emulsifier 2.5% glidant 0.4% dextrose compressible 95.0% flavor modifier 0.1%

[00175] Example Composition 7 may be administered at a preventive or use dose of 1 tablet per day, an onset dose of 2 to 4 tablets per day, and/or an enhanced dose of 5 tablets per day.

Example 8

[00176] A carmabinoid composition (Example Composition 8) was prepared in accordance with the following formula. Example Composition 8 was in the form of a gummy candy and met the following criteria: Unit/dose amount of 4.5 g, CBD dose of 10 mg/gummy candy, CBG dose of 1 mg/ gummy candy, Zinc dose of 10 mg/ gummy candy, and Quercetin dose of 15 mg/ gummy candy.

Example Composition 8

Component % by weight

CBD isolate 0.2% CBG isolate 0.02%

Quercetin 0.2%

Solubilizer 0.7%

Emulsifier 0.2% water 40.5%

Plasticizing agent 3.7% gelatin 8.1%

Preservative 0.05% pH adjustment/buffer 1.5% sugar 42.6%

Zinc gluconate 0.9% color 0.1% flavoring agent 1.2%

[00177] Example Composition 8 may be administered at a preventive or use dose 1 gummy candy per day, an onset dose of 2 to 4 gummy candies per day, and/or an enhanced dose of 5 to 6 gummy candy day.

Example 9

[00178] A cannabinoid composition (Example Composition 9) was prepared in accordance with the following formula. Example Composition 9 was in the form of a tablet and met the following criteria: Unit/dose amount of 4.5 g, CBD dose of 5 mg/tablet, CBG dose of 5 mg/tablet, Zinc dose of 10 mg/tablet, and Quercetin dose of 10 mg/tablet.

Example Composition 9

Component % by weight

CBD isolate 0.1%

CBG isolate 0.1%

Quercetin 0.2%

Solubilizer 0.7%

Emulsifier 0.2% water 40.5%

Plasticizing agent 3.7% gelatin 8.1% Preservative 0.05% pH adjustment/buffer 1.5% sugar 42.6%

Zinc gluconate 0.9% color 0.1% flavoring agent 1.2%

Example 10

[00179] A cannabinoid composition (Example Composition 10) was prepared in accordance with the following formula. Example Composition 10 was in the form of an oral strip and met the following criteria: Unit/dose amount of 50 mg, CBD dose of 5 mg/strip, CBG dose of 2.5 mg/strip, zinc dose of 1 mg/strip, and terpenes dose of 10 mg/strip.

[00180]

Example Composition 10

Component % by weight

CBD isolate 0.9%

CBG isolate 0.4%

Zinc ionophore 0.4% emulsifier 1.8% solubilizer 3.6% water 25.3% flavor modifier 0.3% binder A 42.2% plasticizing agent 16.9% film former 1.3% zinc citrate, encapsulated 4.5% flavoring agent (eucalyptus oil, peppermint 2.1% oil) 0.8% color

Example 11

[00181] A cannabinoid composition (Example Composition 11) was prepared in accordance with the following formula. Example Composition 11 was in the form of a capsule and met the following criteria: Unit/dose amount of 0.6 g/capsule, CBD dose of 10 mg/capsule, Zinc dose of 10 mg/capsule, polyphenol dose of 100 mg/capsule, Vitamin C dose of 100 mg/capsule, and zinc ionophore (epigallocatechin gallate) dose of 45 mg/capsule.

Example Composition 11

Component % by weight

CBD isolate 1.8%

Zinc dtrate 1.7%

Berries Blend extract 33.3%

Green Tea extract 16.7%

Vitamin C 16.7% magnesium stearate 29.8%

Example 12

[00182] A cannabinoid composition (Example Composition 12) was prepared in accordance with the following formula. Example Composition 12 was in the form of a capsule and met the following criteria: Unit/dose amount of 0.6 g/capsule, CBD dose of 30 mg/capsule, Zinc dose of 40 mg/capsule, polyphenol dose of 100 mg/capsule, Vitamin C dose of 100 mg/capsule, and zinc ionophore (epigallocatechin gallate) dose of 90 mg/capsule.

Example Composition 12

Component % by weight

CBD isolate 5.2%

Zinc dtrate 6.7%

Berries Blend extrad 33.3%

Green Tea extract 33.3%

Vitamin C 16.7% magnesium stearate 4.8%

Example 13

[00183] A cannabinoid composition (Example Composition 13) was prepared in accordance with the following formula. Example Composition 13 was in the form of an oral spray and met the following criteria: Unit/dose amount of 0.13 mL/spray, CBD dose of 2.5 mg/spray, Zinc dose of 3 mg/spray, terpenes dose of 7 mg/spray, and zinc ionophore (epigallocatechin gallate) dose of 3 mg/spray. Example Composition 13

Component % by weight water 57% sugar 5% co-solvent 10% humectant 5% zinc sulfate 14%

CBD distillate 2% emulsifier 2% suspending agent 1% zinc ionophore 2% eucalyptus oil 0.2% peppermint oil 0.2% antioxidant 1% buffering agent 0.1% chelating agent 0.1% preservative 0.05% pH adjustment/buffer 0.15% flavour modifier 0.5%

Example 14

[00184] A cannabinoid composition (Example Composition 14) was prepared in accordance with the following formula. Example Composition 14 was in the form of a nasal spray and met the following criteria: Unit/dose amount of 0.1 mL/spray, CBD dose of 0.5 mg/spray, zinc dose of 0.5 mg/spray, and terpenes dose of 1 mg/spray.

Example Composition 14

Component % by weight water 44% co-solvent A 25% buffering agent 1% xylitol 15% zinc gluconate 12% co-solvent B 1.2% emusifier 0.6%

CBD isolate 0.6% aloe vera extract 0.5% rosemary extract 0.5% preservative 0.05%

Example 15

[00185] A carmabinoid composition (Example Composition 15) was prepared in accordance with the following formula. Example Composition 15 was in the form of a nasal gel and met the following criteria: Unit/dose amount of 0.1 mL, CBD dose of 2.5 mg/0.1 mL, and zinc dose of 3 mg/0.1 mL.

Example Composition 15

Component % by weight water 40% cosolvents 25% hemuctant 2.5% tonicity agent 2% poloxamer 407 16% pH adjustment 0.3% preservative 0.05% suspending agent 2% mucoadhesive agent 0.30% CBD isolate 0.60% zinc gluconate 12%

Example 16

[00186] A carmabinoid composition (Example Composition 16) was prepared in accordance with the following formula. Example Composition 16 was in the form of a powder and met the following criteria: Unit/dose amount of 0.5 g, CBD dose of 10 mg/0.5 g, and zinc dose of 10 mg/0.5 g.

Example Composition 16

Component % by weight buffering agent 3 % antioxidant 5% sweetener 10%

CBD isolate 2% natural flavor 15% pH adjustment/buffer 28% filler 21% glidant 1.5% zinc gluconate 14% color 0.3% preservative 0.4%